nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—FKBP1A—Cyclosporine—psoriasis	0.184	0.299	CbGbCtD
Sirolimus—CYP3A5—Beclomethasone—psoriasis	0.0444	0.0721	CbGbCtD
Sirolimus—SLCO1B1—Mycophenolate mofetil—psoriasis	0.0401	0.0652	CbGbCtD
Sirolimus—SLCO1B1—Cyclosporine—psoriasis	0.0304	0.0494	CbGbCtD
Sirolimus—CYP3A7—Hydrocortisone—psoriasis	0.0189	0.0307	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0189	0.0307	CbGbCtD
Sirolimus—CYP3A7—Cyclosporine—psoriasis	0.0179	0.029	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0179	0.029	CbGbCtD
Sirolimus—CYP3A5—Mycophenolate mofetil—psoriasis	0.0177	0.0287	CbGbCtD
Sirolimus—SLCO1B1—Methotrexate—psoriasis	0.0161	0.0262	CbGbCtD
Sirolimus—CYP3A4—Calcitriol—psoriasis	0.0154	0.0251	CbGbCtD
Sirolimus—CYP3A5—Hydrocortisone—psoriasis	0.0142	0.023	CbGbCtD
Sirolimus—CYP3A5—Cyclosporine—psoriasis	0.0134	0.0218	CbGbCtD
Sirolimus—CYP3A4—Methoxsalen—psoriasis	0.012	0.0195	CbGbCtD
Sirolimus—CYP3A7—Dexamethasone—psoriasis	0.0118	0.0191	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0118	0.0191	CbGbCtD
Sirolimus—ABCB1—Mycophenolate mofetil—psoriasis	0.0115	0.0187	CbGbCtD
Sirolimus—ABCB1—Betamethasone—psoriasis	0.00987	0.016	CbGbCtD
Sirolimus—ABCB1—Prednisolone—psoriasis	0.00973	0.0158	CbGbCtD
Sirolimus—ABCB1—Hydrocortisone—psoriasis	0.00923	0.015	CbGbCtD
Sirolimus—ABCB1—Prednisone—psoriasis	0.00919	0.0149	CbGbCtD
Sirolimus—CYP3A5—Dexamethasone—psoriasis	0.00882	0.0143	CbGbCtD
Sirolimus—ABCB1—Cyclosporine—psoriasis	0.00871	0.0142	CbGbCtD
Sirolimus—CYP3A4—Cholecalciferol—psoriasis	0.00795	0.0129	CbGbCtD
Sirolimus—CYP3A4—Triamcinolone—psoriasis	0.00689	0.0112	CbGbCtD
Sirolimus—CYP3A4—Mycophenolate mofetil—psoriasis	0.00689	0.0112	CbGbCtD
Sirolimus—CYP3A4—Betamethasone—psoriasis	0.00591	0.0096	CbGbCtD
Sirolimus—CYP3A4—Prednisolone—psoriasis	0.00583	0.00948	CbGbCtD
Sirolimus—ABCB1—Dexamethasone—psoriasis	0.00574	0.00932	CbGbCtD
Sirolimus—CYP3A4—Hydrocortisone—psoriasis	0.00553	0.00898	CbGbCtD
Sirolimus—CYP3A4—Prednisone—psoriasis	0.00551	0.00895	CbGbCtD
Sirolimus—CYP3A4—Cyclosporine—psoriasis	0.00522	0.00848	CbGbCtD
Sirolimus—ABCB1—Methotrexate—psoriasis	0.00461	0.00749	CbGbCtD
Sirolimus—CYP3A4—Dexamethasone—psoriasis	0.00344	0.00559	CbGbCtD
Sirolimus—FGF2—Signaling by ERBB4—IL6—psoriasis	5.25e-05	0.000594	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—IL6—psoriasis	5.23e-05	0.000593	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CRP—psoriasis	5.18e-05	0.000586	CbGpPWpGaD
Sirolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—psoriasis	5.16e-05	0.000584	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—NFKB1—psoriasis	5.08e-05	0.000576	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of proteins—CXCL8—psoriasis	5.05e-05	0.000572	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—NFKB1—psoriasis	5.04e-05	0.000571	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—CXCL8—psoriasis	5.04e-05	0.000571	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—IL6—psoriasis	5.01e-05	0.000568	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—IL6—psoriasis	4.99e-05	0.000565	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HLA-A—psoriasis	4.97e-05	0.000563	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—IL6—psoriasis	4.96e-05	0.000562	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—HLA-DRB1—psoriasis	4.96e-05	0.000562	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CRP—psoriasis	4.94e-05	0.00056	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—IL6—psoriasis	4.94e-05	0.000559	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—STAT3—psoriasis	4.93e-05	0.000559	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—IL6—psoriasis	4.87e-05	0.000551	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—SOCS1—psoriasis	4.86e-05	0.000551	CbGpPWpGaD
Sirolimus—MTOR—Signaling by Insulin receptor—IL6—psoriasis	4.83e-05	0.000548	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—STAT3—psoriasis	4.83e-05	0.000547	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—TYK2—psoriasis	4.8e-05	0.000544	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	4.77e-05	0.000541	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—PPARG—psoriasis	4.77e-05	0.00054	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—ICAM1—psoriasis	4.76e-05	0.000539	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ITGAL—psoriasis	4.75e-05	0.000538	CbGpPWpGaD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.72e-05	0.000535	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—NFKBIA—psoriasis	4.72e-05	0.000535	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—SOCS1—psoriasis	4.67e-05	0.000529	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—NDUFA5—psoriasis	4.64e-05	0.000526	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—IL6—psoriasis	4.64e-05	0.000526	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	4.64e-05	0.000526	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—IL6—psoriasis	4.64e-05	0.000526	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—IL6—psoriasis	4.6e-05	0.000522	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HLA-E—psoriasis	4.57e-05	0.000518	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—IL6—psoriasis	4.56e-05	0.000517	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HLA-DRB1—psoriasis	4.54e-05	0.000515	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—IL6—psoriasis	4.54e-05	0.000515	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—STAT3—psoriasis	4.53e-05	0.000513	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—NFKBIA—psoriasis	4.5e-05	0.00051	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCL20—psoriasis	4.48e-05	0.000508	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—CXCL8—psoriasis	4.46e-05	0.000505	CbGpPWpGaD
Sirolimus—MTOR—Immune System—REL—psoriasis	4.44e-05	0.000503	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—SOCS1—psoriasis	4.44e-05	0.000503	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—PPARG—psoriasis	4.39e-05	0.000497	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	4.37e-05	0.000495	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—ICAM1—psoriasis	4.36e-05	0.000494	CbGpPWpGaD
Sirolimus—Loss of consciousness—Betamethasone—psoriasis	4.36e-05	0.000147	CcSEcCtD
Sirolimus—Dizziness—Mycophenolic acid—psoriasis	4.36e-05	0.000147	CcSEcCtD
Sirolimus—Epistaxis—Methotrexate—psoriasis	4.36e-05	0.000147	CcSEcCtD
Sirolimus—Paraesthesia—Prednisolone—psoriasis	4.36e-05	0.000147	CcSEcCtD
Sirolimus—Tachycardia—Triamcinolone—psoriasis	4.35e-05	0.000147	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—NFKBIA—psoriasis	4.33e-05	0.00049	CbGpPWpGaD
Sirolimus—Malnutrition—Prednisone—psoriasis	4.32e-05	0.000146	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Hydrocortisone—psoriasis	4.32e-05	0.000146	CcSEcCtD
Sirolimus—Hyperhidrosis—Triamcinolone—psoriasis	4.31e-05	0.000146	CcSEcCtD
Sirolimus—MTOR—Immune System—IFIH1—psoriasis	4.31e-05	0.000488	CbGpPWpGaD
Sirolimus—Feeling abnormal—Mycophenolate mofetil—psoriasis	4.29e-05	0.000145	CcSEcCtD
Sirolimus—Insomnia—Hydrocortisone—psoriasis	4.29e-05	0.000145	CcSEcCtD
Sirolimus—Hypertension—Dexamethasone—psoriasis	4.28e-05	0.000145	CcSEcCtD
Sirolimus—Hypertension—Betamethasone—psoriasis	4.28e-05	0.000145	CcSEcCtD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—psoriasis	4.28e-05	0.000484	CbGpPWpGaD
Sirolimus—Paraesthesia—Hydrocortisone—psoriasis	4.25e-05	0.000144	CcSEcCtD
Sirolimus—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	4.25e-05	0.000144	CcSEcCtD
Sirolimus—Myalgia—Betamethasone—psoriasis	4.22e-05	0.000143	CcSEcCtD
Sirolimus—Myalgia—Dexamethasone—psoriasis	4.22e-05	0.000143	CcSEcCtD
Sirolimus—Body temperature increased—Cyclosporine—psoriasis	4.21e-05	0.000142	CcSEcCtD
Sirolimus—Abdominal pain—Cyclosporine—psoriasis	4.21e-05	0.000142	CcSEcCtD
Sirolimus—Anxiety—Betamethasone—psoriasis	4.21e-05	0.000142	CcSEcCtD
Sirolimus—Anxiety—Dexamethasone—psoriasis	4.21e-05	0.000142	CcSEcCtD
Sirolimus—Vomiting—Mycophenolic acid—psoriasis	4.19e-05	0.000141	CcSEcCtD
Sirolimus—FGF2—Developmental Biology—TYK2—psoriasis	4.18e-05	0.000473	CbGpPWpGaD
Sirolimus—Discomfort—Betamethasone—psoriasis	4.17e-05	0.000141	CcSEcCtD
Sirolimus—Discomfort—Dexamethasone—psoriasis	4.17e-05	0.000141	CcSEcCtD
Sirolimus—Dyspepsia—Hydrocortisone—psoriasis	4.17e-05	0.000141	CcSEcCtD
Sirolimus—Haemoglobin—Methotrexate—psoriasis	4.17e-05	0.000141	CcSEcCtD
Sirolimus—Rash—Mycophenolic acid—psoriasis	4.15e-05	0.00014	CcSEcCtD
Sirolimus—Dermatitis—Mycophenolic acid—psoriasis	4.15e-05	0.00014	CcSEcCtD
Sirolimus—Pain—Prednisolone—psoriasis	4.15e-05	0.00014	CcSEcCtD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	4.15e-05	0.00047	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HLA-B—psoriasis	4.15e-05	0.00047	CbGpPWpGaD
Sirolimus—Haemorrhage—Methotrexate—psoriasis	4.15e-05	0.00014	CcSEcCtD
Sirolimus—MTOR—Cellular responses to stress—JUN—psoriasis	4.14e-05	0.000469	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD8A—psoriasis	4.14e-05	0.000469	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—IL6—psoriasis	4.13e-05	0.000468	CbGpPWpGaD
Sirolimus—Headache—Mycophenolic acid—psoriasis	4.13e-05	0.000139	CcSEcCtD
Sirolimus—Decreased appetite—Hydrocortisone—psoriasis	4.12e-05	0.000139	CcSEcCtD
Sirolimus—Pharyngitis—Methotrexate—psoriasis	4.12e-05	0.000139	CcSEcCtD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	4.11e-05	0.000466	CbGpPWpGaD
Sirolimus—Abdominal pain—Mycophenolate mofetil—psoriasis	4.11e-05	0.000139	CcSEcCtD
Sirolimus—Body temperature increased—Mycophenolate mofetil—psoriasis	4.11e-05	0.000139	CcSEcCtD
Sirolimus—Urinary tract disorder—Methotrexate—psoriasis	4.1e-05	0.000138	CcSEcCtD
Sirolimus—ABCB1—Allograft Rejection—VEGFA—psoriasis	4.09e-05	0.000463	CbGpPWpGaD
Sirolimus—Gastrointestinal disorder—Hydrocortisone—psoriasis	4.09e-05	0.000138	CcSEcCtD
Sirolimus—MTOR—Immune System—HLA-C—psoriasis	4.08e-05	0.000463	CbGpPWpGaD
Sirolimus—Urethral disorder—Methotrexate—psoriasis	4.06e-05	0.000137	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Triamcinolone—psoriasis	4.06e-05	0.000137	CcSEcCtD
Sirolimus—Pain—Hydrocortisone—psoriasis	4.05e-05	0.000137	CcSEcCtD
Sirolimus—Oedema—Betamethasone—psoriasis	4.05e-05	0.000137	CcSEcCtD
Sirolimus—Anaphylactic shock—Dexamethasone—psoriasis	4.05e-05	0.000137	CcSEcCtD
Sirolimus—Anaphylactic shock—Betamethasone—psoriasis	4.05e-05	0.000137	CcSEcCtD
Sirolimus—Oedema—Dexamethasone—psoriasis	4.05e-05	0.000137	CcSEcCtD
Sirolimus—Insomnia—Triamcinolone—psoriasis	4.03e-05	0.000136	CcSEcCtD
Sirolimus—MTOR—Immune System—TNFAIP3—psoriasis	4.03e-05	0.000457	CbGpPWpGaD
Sirolimus—Infection—Betamethasone—psoriasis	4.02e-05	0.000136	CcSEcCtD
Sirolimus—Infection—Dexamethasone—psoriasis	4.02e-05	0.000136	CcSEcCtD
Sirolimus—Ill-defined disorder—Prednisone—psoriasis	4.01e-05	0.000135	CcSEcCtD
Sirolimus—Paraesthesia—Triamcinolone—psoriasis	4.01e-05	0.000135	CcSEcCtD
Sirolimus—Feeling abnormal—Prednisolone—psoriasis	4e-05	0.000135	CcSEcCtD
Sirolimus—Visual impairment—Methotrexate—psoriasis	4e-05	0.000135	CcSEcCtD
Sirolimus—Anaemia—Prednisone—psoriasis	3.99e-05	0.000135	CcSEcCtD
Sirolimus—MTOR—Cellular responses to stress—NFKB1—psoriasis	3.99e-05	0.000452	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HLA-B—psoriasis	3.98e-05	0.000451	CbGpPWpGaD
Sirolimus—Shock—Betamethasone—psoriasis	3.98e-05	0.000134	CcSEcCtD
Sirolimus—Shock—Dexamethasone—psoriasis	3.98e-05	0.000134	CcSEcCtD
Sirolimus—Dyspnoea—Triamcinolone—psoriasis	3.98e-05	0.000134	CcSEcCtD
Sirolimus—Nervous system disorder—Dexamethasone—psoriasis	3.97e-05	0.000134	CcSEcCtD
Sirolimus—Nervous system disorder—Betamethasone—psoriasis	3.97e-05	0.000134	CcSEcCtD
Sirolimus—Agitation—Prednisone—psoriasis	3.97e-05	0.000134	CcSEcCtD
Sirolimus—Thrombocytopenia—Dexamethasone—psoriasis	3.96e-05	0.000134	CcSEcCtD
Sirolimus—Thrombocytopenia—Betamethasone—psoriasis	3.96e-05	0.000134	CcSEcCtD
Sirolimus—MTOR—Downstream signaling of activated FGFR—IL6—psoriasis	3.96e-05	0.000448	CbGpPWpGaD
Sirolimus—Tachycardia—Betamethasone—psoriasis	3.95e-05	0.000133	CcSEcCtD
Sirolimus—Tachycardia—Dexamethasone—psoriasis	3.95e-05	0.000133	CcSEcCtD
Sirolimus—CYP3A5—Metabolism—CYP2S1—psoriasis	3.95e-05	0.000447	CbGpPWpGaD
Sirolimus—Angioedema—Prednisone—psoriasis	3.95e-05	0.000133	CcSEcCtD
Sirolimus—Hypersensitivity—Cyclosporine—psoriasis	3.93e-05	0.000133	CcSEcCtD
Sirolimus—Dyspepsia—Triamcinolone—psoriasis	3.93e-05	0.000133	CcSEcCtD
Sirolimus—Nausea—Mycophenolic acid—psoriasis	3.91e-05	0.000132	CcSEcCtD
Sirolimus—Hyperhidrosis—Dexamethasone—psoriasis	3.91e-05	0.000132	CcSEcCtD
Sirolimus—Hyperhidrosis—Betamethasone—psoriasis	3.91e-05	0.000132	CcSEcCtD
Sirolimus—Feeling abnormal—Hydrocortisone—psoriasis	3.9e-05	0.000132	CcSEcCtD
Sirolimus—Malaise—Prednisone—psoriasis	3.9e-05	0.000131	CcSEcCtD
Sirolimus—MTOR—Signaling by ERBB4—IL6—psoriasis	3.89e-05	0.000441	CbGpPWpGaD
Sirolimus—Gastrointestinal pain—Hydrocortisone—psoriasis	3.87e-05	0.000131	CcSEcCtD
Sirolimus—Syncope—Prednisone—psoriasis	3.87e-05	0.000131	CcSEcCtD
Sirolimus—Tinnitus—Methotrexate—psoriasis	3.87e-05	0.00013	CcSEcCtD
Sirolimus—EIF4E—Immune System—TYK2—psoriasis	3.87e-05	0.000438	CbGpPWpGaD
Sirolimus—Anorexia—Dexamethasone—psoriasis	3.86e-05	0.00013	CcSEcCtD
Sirolimus—Anorexia—Betamethasone—psoriasis	3.86e-05	0.00013	CcSEcCtD
Sirolimus—Cardiac disorder—Methotrexate—psoriasis	3.85e-05	0.00013	CcSEcCtD
Sirolimus—Hypersensitivity—Mycophenolate mofetil—psoriasis	3.83e-05	0.000129	CcSEcCtD
Sirolimus—Asthenia—Cyclosporine—psoriasis	3.82e-05	0.000129	CcSEcCtD
Sirolimus—FGF2—Immune System—SOCS1—psoriasis	3.82e-05	0.000432	CbGpPWpGaD
Sirolimus—Pain—Triamcinolone—psoriasis	3.81e-05	0.000129	CcSEcCtD
Sirolimus—Loss of consciousness—Prednisone—psoriasis	3.8e-05	0.000128	CcSEcCtD
Sirolimus—Hypotension—Dexamethasone—psoriasis	3.78e-05	0.000128	CcSEcCtD
Sirolimus—Hypotension—Betamethasone—psoriasis	3.78e-05	0.000128	CcSEcCtD
Sirolimus—Pruritus—Cyclosporine—psoriasis	3.77e-05	0.000127	CcSEcCtD
Sirolimus—Angiopathy—Methotrexate—psoriasis	3.76e-05	0.000127	CcSEcCtD
Sirolimus—Immune system disorder—Methotrexate—psoriasis	3.75e-05	0.000126	CcSEcCtD
Sirolimus—Body temperature increased—Hydrocortisone—psoriasis	3.75e-05	0.000126	CcSEcCtD
Sirolimus—Abdominal pain—Hydrocortisone—psoriasis	3.75e-05	0.000126	CcSEcCtD
Sirolimus—MTOR—Signaling by NGF—NFKB1—psoriasis	3.74e-05	0.000424	CbGpPWpGaD
Sirolimus—Mediastinal disorder—Methotrexate—psoriasis	3.74e-05	0.000126	CcSEcCtD
Sirolimus—Asthenia—Mycophenolate mofetil—psoriasis	3.73e-05	0.000126	CcSEcCtD
Sirolimus—Hypertension—Prednisone—psoriasis	3.73e-05	0.000126	CcSEcCtD
Sirolimus—Chills—Methotrexate—psoriasis	3.72e-05	0.000126	CcSEcCtD
Sirolimus—MTOR—Downstream signal transduction—IL6—psoriasis	3.72e-05	0.000421	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—IL6—psoriasis	3.7e-05	0.000419	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HLA-A—psoriasis	3.69e-05	0.000418	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—TYK2—psoriasis	3.69e-05	0.000418	CbGpPWpGaD
Sirolimus—Musculoskeletal discomfort—Dexamethasone—psoriasis	3.69e-05	0.000124	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Betamethasone—psoriasis	3.69e-05	0.000124	CcSEcCtD
Sirolimus—MTOR—Signaling by ERBB2—IL6—psoriasis	3.68e-05	0.000417	CbGpPWpGaD
Sirolimus—Pruritus—Mycophenolate mofetil—psoriasis	3.68e-05	0.000124	CcSEcCtD
Sirolimus—Myalgia—Prednisone—psoriasis	3.68e-05	0.000124	CcSEcCtD
Sirolimus—Arthralgia—Prednisone—psoriasis	3.68e-05	0.000124	CcSEcCtD
Sirolimus—Feeling abnormal—Triamcinolone—psoriasis	3.68e-05	0.000124	CcSEcCtD
Sirolimus—FKBP1A—Disease—HLA-A—psoriasis	3.67e-05	0.000416	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CRP—psoriasis	3.67e-05	0.000415	CbGpPWpGaD
Sirolimus—Anxiety—Prednisone—psoriasis	3.66e-05	0.000124	CcSEcCtD
Sirolimus—MTOR—DAP12 signaling—IL6—psoriasis	3.66e-05	0.000415	CbGpPWpGaD
Sirolimus—Insomnia—Betamethasone—psoriasis	3.66e-05	0.000124	CcSEcCtD
Sirolimus—Insomnia—Dexamethasone—psoriasis	3.66e-05	0.000124	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	3.65e-05	0.000123	CcSEcCtD
Sirolimus—Diarrhoea—Cyclosporine—psoriasis	3.65e-05	0.000123	CcSEcCtD
Sirolimus—Paraesthesia—Dexamethasone—psoriasis	3.63e-05	0.000123	CcSEcCtD
Sirolimus—Paraesthesia—Betamethasone—psoriasis	3.63e-05	0.000123	CcSEcCtD
Sirolimus—Discomfort—Prednisone—psoriasis	3.63e-05	0.000123	CcSEcCtD
Sirolimus—EIF4E—Immune System—IFNG—psoriasis	3.62e-05	0.00041	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—VEGFA—psoriasis	3.62e-05	0.00041	CbGpPWpGaD
Sirolimus—Malnutrition—Methotrexate—psoriasis	3.61e-05	0.000122	CcSEcCtD
Sirolimus—MTOR—Cellular responses to stress—STAT3—psoriasis	3.58e-05	0.000406	CbGpPWpGaD
Sirolimus—Hypersensitivity—Prednisolone—psoriasis	3.57e-05	0.000121	CcSEcCtD
Sirolimus—Dyspepsia—Dexamethasone—psoriasis	3.56e-05	0.00012	CcSEcCtD
Sirolimus—Dyspepsia—Betamethasone—psoriasis	3.56e-05	0.00012	CcSEcCtD
Sirolimus—Diarrhoea—Mycophenolate mofetil—psoriasis	3.56e-05	0.00012	CcSEcCtD
Sirolimus—Body temperature increased—Triamcinolone—psoriasis	3.53e-05	0.000119	CcSEcCtD
Sirolimus—Dizziness—Cyclosporine—psoriasis	3.53e-05	0.000119	CcSEcCtD
Sirolimus—Oedema—Prednisone—psoriasis	3.53e-05	0.000119	CcSEcCtD
Sirolimus—Anaphylactic shock—Prednisone—psoriasis	3.53e-05	0.000119	CcSEcCtD
Sirolimus—Decreased appetite—Dexamethasone—psoriasis	3.52e-05	0.000119	CcSEcCtD
Sirolimus—Decreased appetite—Betamethasone—psoriasis	3.52e-05	0.000119	CcSEcCtD
Sirolimus—ABCB1—Allograft Rejection—TNF—psoriasis	3.51e-05	0.000397	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NDUFA5—psoriasis	3.5e-05	0.000397	CbGpPWpGaD
Sirolimus—Infection—Prednisone—psoriasis	3.5e-05	0.000118	CcSEcCtD
Sirolimus—EIF4E—Immune System—CD4—psoriasis	3.5e-05	0.000396	CbGpPWpGaD
Sirolimus—Gastrointestinal disorder—Betamethasone—psoriasis	3.49e-05	0.000118	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Dexamethasone—psoriasis	3.49e-05	0.000118	CcSEcCtD
Sirolimus—Back pain—Methotrexate—psoriasis	3.49e-05	0.000118	CcSEcCtD
Sirolimus—Hypersensitivity—Hydrocortisone—psoriasis	3.49e-05	0.000118	CcSEcCtD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.49e-05	0.000395	CbGpPWpGaD
Sirolimus—Shock—Prednisone—psoriasis	3.47e-05	0.000117	CcSEcCtD
Sirolimus—Pain—Betamethasone—psoriasis	3.46e-05	0.000117	CcSEcCtD
Sirolimus—Pain—Dexamethasone—psoriasis	3.46e-05	0.000117	CcSEcCtD
Sirolimus—Nervous system disorder—Prednisone—psoriasis	3.46e-05	0.000117	CcSEcCtD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	3.45e-05	0.000391	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—IL6—psoriasis	3.45e-05	0.000391	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—IL6—psoriasis	3.45e-05	0.000391	CbGpPWpGaD
Sirolimus—Tachycardia—Prednisone—psoriasis	3.44e-05	0.000116	CcSEcCtD
Sirolimus—Dizziness—Mycophenolate mofetil—psoriasis	3.44e-05	0.000116	CcSEcCtD
Sirolimus—FKBP1A—Disease—APOE—psoriasis	3.43e-05	0.000389	CbGpPWpGaD
Sirolimus—Skin disorder—Prednisone—psoriasis	3.42e-05	0.000116	CcSEcCtD
Sirolimus—MTOR—Signaling by EGFR—IL6—psoriasis	3.42e-05	0.000387	CbGpPWpGaD
Sirolimus—Hyperhidrosis—Prednisone—psoriasis	3.41e-05	0.000115	CcSEcCtD
Sirolimus—Asthenia—Hydrocortisone—psoriasis	3.4e-05	0.000115	CcSEcCtD
Sirolimus—MTOR—Immune System—HLA-E—psoriasis	3.39e-05	0.000384	CbGpPWpGaD
Sirolimus—Vomiting—Cyclosporine—psoriasis	3.39e-05	0.000114	CcSEcCtD
Sirolimus—MTOR—Signaling by EGFR in Cancer—IL6—psoriasis	3.39e-05	0.000384	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD8A—psoriasis	3.38e-05	0.000383	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HLA-DRB1—psoriasis	3.37e-05	0.000382	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—IL6—psoriasis	3.37e-05	0.000382	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—STAT3—psoriasis	3.36e-05	0.000381	CbGpPWpGaD
Sirolimus—Rash—Cyclosporine—psoriasis	3.36e-05	0.000113	CcSEcCtD
Sirolimus—Anorexia—Prednisone—psoriasis	3.36e-05	0.000113	CcSEcCtD
Sirolimus—Dermatitis—Cyclosporine—psoriasis	3.36e-05	0.000113	CcSEcCtD
Sirolimus—Pruritus—Hydrocortisone—psoriasis	3.35e-05	0.000113	CcSEcCtD
Sirolimus—Ill-defined disorder—Methotrexate—psoriasis	3.35e-05	0.000113	CcSEcCtD
Sirolimus—MTOR—Innate Immune System—NFKBIA—psoriasis	3.34e-05	0.000379	CbGpPWpGaD
Sirolimus—Headache—Cyclosporine—psoriasis	3.34e-05	0.000113	CcSEcCtD
Sirolimus—FGF2—Innate Immune System—CD4—psoriasis	3.34e-05	0.000378	CbGpPWpGaD
Sirolimus—Anaemia—Methotrexate—psoriasis	3.34e-05	0.000113	CcSEcCtD
Sirolimus—Feeling abnormal—Betamethasone—psoriasis	3.34e-05	0.000113	CcSEcCtD
Sirolimus—Feeling abnormal—Dexamethasone—psoriasis	3.34e-05	0.000113	CcSEcCtD
Sirolimus—MTOR—Signaling Pathways—CCL20—psoriasis	3.32e-05	0.000377	CbGpPWpGaD
Sirolimus—Gastrointestinal pain—Dexamethasone—psoriasis	3.31e-05	0.000112	CcSEcCtD
Sirolimus—Gastrointestinal pain—Betamethasone—psoriasis	3.31e-05	0.000112	CcSEcCtD
Sirolimus—Vomiting—Mycophenolate mofetil—psoriasis	3.31e-05	0.000112	CcSEcCtD
Sirolimus—Hypersensitivity—Triamcinolone—psoriasis	3.29e-05	0.000111	CcSEcCtD
Sirolimus—Rash—Mycophenolate mofetil—psoriasis	3.28e-05	0.000111	CcSEcCtD
Sirolimus—Dermatitis—Mycophenolate mofetil—psoriasis	3.28e-05	0.000111	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—LEP—psoriasis	3.27e-05	0.000371	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—APOE—psoriasis	3.27e-05	0.000371	CbGpPWpGaD
Sirolimus—Headache—Mycophenolate mofetil—psoriasis	3.26e-05	0.00011	CcSEcCtD
Sirolimus—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	3.26e-05	0.000369	CbGpPWpGaD
Sirolimus—Malaise—Methotrexate—psoriasis	3.26e-05	0.00011	CcSEcCtD
Sirolimus—FGF2—Developmental Biology—NFKB1—psoriasis	3.26e-05	0.000369	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HLA-B—psoriasis	3.25e-05	0.000369	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SOCS1—psoriasis	3.25e-05	0.000369	CbGpPWpGaD
Sirolimus—Diarrhoea—Hydrocortisone—psoriasis	3.24e-05	0.000109	CcSEcCtD
Sirolimus—MTOR—Adaptive Immune System—ICAM1—psoriasis	3.24e-05	0.000367	CbGpPWpGaD
Sirolimus—Leukopenia—Methotrexate—psoriasis	3.23e-05	0.000109	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Prednisone—psoriasis	3.21e-05	0.000108	CcSEcCtD
Sirolimus—MTOR—Adaptive Immune System—NFKBIA—psoriasis	3.21e-05	0.000364	CbGpPWpGaD
Sirolimus—Dizziness—Prednisolone—psoriasis	3.21e-05	0.000108	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—CD4—psoriasis	3.2e-05	0.000363	CbGpPWpGaD
Sirolimus—Asthenia—Triamcinolone—psoriasis	3.2e-05	0.000108	CcSEcCtD
Sirolimus—Abdominal pain—Dexamethasone—psoriasis	3.2e-05	0.000108	CcSEcCtD
Sirolimus—Body temperature increased—Betamethasone—psoriasis	3.2e-05	0.000108	CcSEcCtD
Sirolimus—Body temperature increased—Dexamethasone—psoriasis	3.2e-05	0.000108	CcSEcCtD
Sirolimus—Abdominal pain—Betamethasone—psoriasis	3.2e-05	0.000108	CcSEcCtD
Sirolimus—FKBP1A—Disease—NOS2—psoriasis	3.2e-05	0.000362	CbGpPWpGaD
Sirolimus—Insomnia—Prednisone—psoriasis	3.19e-05	0.000108	CcSEcCtD
Sirolimus—Nausea—Cyclosporine—psoriasis	3.17e-05	0.000107	CcSEcCtD
Sirolimus—Paraesthesia—Prednisone—psoriasis	3.17e-05	0.000107	CcSEcCtD
Sirolimus—FGF2—Signaling by NGF—IL6—psoriasis	3.16e-05	0.000358	CbGpPWpGaD
Sirolimus—Pruritus—Triamcinolone—psoriasis	3.16e-05	0.000107	CcSEcCtD
Sirolimus—Cough—Methotrexate—psoriasis	3.15e-05	0.000106	CcSEcCtD
Sirolimus—Dizziness—Hydrocortisone—psoriasis	3.13e-05	0.000106	CcSEcCtD
Sirolimus—EIF4E—Immune System—JUN—psoriasis	3.13e-05	0.000355	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.12e-05	0.000353	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	3.11e-05	0.000352	CbGpPWpGaD
Sirolimus—Dyspepsia—Prednisone—psoriasis	3.1e-05	0.000105	CcSEcCtD
Sirolimus—Nausea—Mycophenolate mofetil—psoriasis	3.09e-05	0.000104	CcSEcCtD
Sirolimus—Arthralgia—Methotrexate—psoriasis	3.07e-05	0.000104	CcSEcCtD
Sirolimus—Chest pain—Methotrexate—psoriasis	3.07e-05	0.000104	CcSEcCtD
Sirolimus—Myalgia—Methotrexate—psoriasis	3.07e-05	0.000104	CcSEcCtD
Sirolimus—Decreased appetite—Prednisone—psoriasis	3.06e-05	0.000103	CcSEcCtD
Sirolimus—Rash—Prednisolone—psoriasis	3.06e-05	0.000103	CcSEcCtD
Sirolimus—Dermatitis—Prednisolone—psoriasis	3.06e-05	0.000103	CcSEcCtD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	3.05e-05	0.000346	CbGpPWpGaD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	3.05e-05	0.000103	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—NFKBIA—psoriasis	3.05e-05	0.000346	CbGpPWpGaD
Sirolimus—Headache—Prednisolone—psoriasis	3.04e-05	0.000103	CcSEcCtD
Sirolimus—Discomfort—Methotrexate—psoriasis	3.04e-05	0.000102	CcSEcCtD
Sirolimus—FGF2—Immune System—HLA-A—psoriasis	3.02e-05	0.000342	CbGpPWpGaD
Sirolimus—Constipation—Prednisone—psoriasis	3.01e-05	0.000102	CcSEcCtD
Sirolimus—Vomiting—Hydrocortisone—psoriasis	3.01e-05	0.000102	CcSEcCtD
Sirolimus—EIF4E—Immune System—NFKB1—psoriasis	3.01e-05	0.000341	CbGpPWpGaD
Sirolimus—Rash—Hydrocortisone—psoriasis	2.99e-05	0.000101	CcSEcCtD
Sirolimus—FGF2—Innate Immune System—JUN—psoriasis	2.99e-05	0.000338	CbGpPWpGaD
Sirolimus—Dermatitis—Hydrocortisone—psoriasis	2.98e-05	0.000101	CcSEcCtD
Sirolimus—ABCB1—Metabolism—CYP2S1—psoriasis	2.98e-05	0.000338	CbGpPWpGaD
Sirolimus—Confusional state—Methotrexate—psoriasis	2.97e-05	0.0001	CcSEcCtD
Sirolimus—Headache—Hydrocortisone—psoriasis	2.97e-05	0.0001	CcSEcCtD
Sirolimus—FGF2—Developmental Biology—VEGFA—psoriasis	2.95e-05	0.000335	CbGpPWpGaD
Sirolimus—Dizziness—Triamcinolone—psoriasis	2.95e-05	9.96e-05	CcSEcCtD
Sirolimus—Anaphylactic shock—Methotrexate—psoriasis	2.95e-05	9.94e-05	CcSEcCtD
Sirolimus—Infection—Methotrexate—psoriasis	2.93e-05	9.88e-05	CcSEcCtD
Sirolimus—FGF2—Developmental Biology—STAT3—psoriasis	2.93e-05	0.000331	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CARM1—psoriasis	2.91e-05	0.000329	CbGpPWpGaD
Sirolimus—Feeling abnormal—Prednisone—psoriasis	2.9e-05	9.8e-05	CcSEcCtD
Sirolimus—Asthenia—Betamethasone—psoriasis	2.9e-05	9.8e-05	CcSEcCtD
Sirolimus—Asthenia—Dexamethasone—psoriasis	2.9e-05	9.8e-05	CcSEcCtD
Sirolimus—Nervous system disorder—Methotrexate—psoriasis	2.89e-05	9.75e-05	CcSEcCtD
Sirolimus—Thrombocytopenia—Methotrexate—psoriasis	2.88e-05	9.74e-05	CcSEcCtD
Sirolimus—Gastrointestinal pain—Prednisone—psoriasis	2.88e-05	9.73e-05	CcSEcCtD
Sirolimus—Nausea—Prednisolone—psoriasis	2.88e-05	9.73e-05	CcSEcCtD
Sirolimus—FGF2—Immune System—CRP—psoriasis	2.88e-05	0.000326	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—NFKB1—psoriasis	2.87e-05	0.000326	CbGpPWpGaD
Sirolimus—Pruritus—Dexamethasone—psoriasis	2.86e-05	9.67e-05	CcSEcCtD
Sirolimus—Pruritus—Betamethasone—psoriasis	2.86e-05	9.67e-05	CcSEcCtD
Sirolimus—Skin disorder—Methotrexate—psoriasis	2.86e-05	9.66e-05	CcSEcCtD
Sirolimus—Hyperhidrosis—Methotrexate—psoriasis	2.85e-05	9.61e-05	CcSEcCtD
Sirolimus—Vomiting—Triamcinolone—psoriasis	2.84e-05	9.57e-05	CcSEcCtD
Sirolimus—MTOR—Immune System—SOCS1—psoriasis	2.83e-05	0.000321	CbGpPWpGaD
Sirolimus—Nausea—Hydrocortisone—psoriasis	2.81e-05	9.5e-05	CcSEcCtD
Sirolimus—Rash—Triamcinolone—psoriasis	2.81e-05	9.49e-05	CcSEcCtD
Sirolimus—Dermatitis—Triamcinolone—psoriasis	2.81e-05	9.48e-05	CcSEcCtD
Sirolimus—Anorexia—Methotrexate—psoriasis	2.81e-05	9.48e-05	CcSEcCtD
Sirolimus—Headache—Triamcinolone—psoriasis	2.79e-05	9.43e-05	CcSEcCtD
Sirolimus—Abdominal pain—Prednisone—psoriasis	2.79e-05	9.41e-05	CcSEcCtD
Sirolimus—Body temperature increased—Prednisone—psoriasis	2.79e-05	9.41e-05	CcSEcCtD
Sirolimus—FGF2—Disease—HLA-A—psoriasis	2.78e-05	0.000315	CbGpPWpGaD
Sirolimus—Diarrhoea—Dexamethasone—psoriasis	2.77e-05	9.35e-05	CcSEcCtD
Sirolimus—Diarrhoea—Betamethasone—psoriasis	2.77e-05	9.35e-05	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—NFKB1—psoriasis	2.76e-05	0.000313	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HLA-DRB1—psoriasis	2.76e-05	0.000312	CbGpPWpGaD
Sirolimus—Hypotension—Methotrexate—psoriasis	2.75e-05	9.29e-05	CcSEcCtD
Sirolimus—MTOR—Innate Immune System—TYK2—psoriasis	2.74e-05	0.00031	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—psoriasis	2.73e-05	0.00031	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.72e-05	0.000308	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—STAT3—psoriasis	2.71e-05	0.000307	CbGpPWpGaD
Sirolimus—Musculoskeletal discomfort—Methotrexate—psoriasis	2.68e-05	9.06e-05	CcSEcCtD
Sirolimus—Dizziness—Betamethasone—psoriasis	2.68e-05	9.03e-05	CcSEcCtD
Sirolimus—Dizziness—Dexamethasone—psoriasis	2.68e-05	9.03e-05	CcSEcCtD
Sirolimus—CYP3A7—Metabolism—CARM1—psoriasis	2.67e-05	0.000302	CbGpPWpGaD
Sirolimus—Insomnia—Methotrexate—psoriasis	2.66e-05	8.99e-05	CcSEcCtD
Sirolimus—Nausea—Triamcinolone—psoriasis	2.65e-05	8.94e-05	CcSEcCtD
Sirolimus—Paraesthesia—Methotrexate—psoriasis	2.65e-05	8.93e-05	CcSEcCtD
Sirolimus—FGF2—Immune System—ICAM1—psoriasis	2.64e-05	0.0003	CbGpPWpGaD
Sirolimus—Dyspnoea—Methotrexate—psoriasis	2.63e-05	8.86e-05	CcSEcCtD
Sirolimus—FGF2—Immune System—NFKBIA—psoriasis	2.62e-05	0.000297	CbGpPWpGaD
Sirolimus—Somnolence—Methotrexate—psoriasis	2.62e-05	8.84e-05	CcSEcCtD
Sirolimus—FKBP1A—Disease—TYK2—psoriasis	2.62e-05	0.000297	CbGpPWpGaD
Sirolimus—FGF2—Disease—APOE—psoriasis	2.6e-05	0.000295	CbGpPWpGaD
Sirolimus—Hypersensitivity—Prednisone—psoriasis	2.6e-05	8.77e-05	CcSEcCtD
Sirolimus—Dyspepsia—Methotrexate—psoriasis	2.59e-05	8.75e-05	CcSEcCtD
Sirolimus—Vomiting—Betamethasone—psoriasis	2.57e-05	8.69e-05	CcSEcCtD
Sirolimus—Vomiting—Dexamethasone—psoriasis	2.57e-05	8.69e-05	CcSEcCtD
Sirolimus—Decreased appetite—Methotrexate—psoriasis	2.56e-05	8.64e-05	CcSEcCtD
Sirolimus—Rash—Betamethasone—psoriasis	2.55e-05	8.61e-05	CcSEcCtD
Sirolimus—Rash—Dexamethasone—psoriasis	2.55e-05	8.61e-05	CcSEcCtD
Sirolimus—Dermatitis—Betamethasone—psoriasis	2.55e-05	8.61e-05	CcSEcCtD
Sirolimus—Dermatitis—Dexamethasone—psoriasis	2.55e-05	8.61e-05	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Methotrexate—psoriasis	2.54e-05	8.58e-05	CcSEcCtD
Sirolimus—Headache—Betamethasone—psoriasis	2.54e-05	8.56e-05	CcSEcCtD
Sirolimus—Headache—Dexamethasone—psoriasis	2.54e-05	8.56e-05	CcSEcCtD
Sirolimus—FGF2—Developmental Biology—TNF—psoriasis	2.53e-05	0.000287	CbGpPWpGaD
Sirolimus—Asthenia—Prednisone—psoriasis	2.53e-05	8.54e-05	CcSEcCtD
Sirolimus—Pain—Methotrexate—psoriasis	2.52e-05	8.5e-05	CcSEcCtD
Sirolimus—MTOR—Immune System—CD8A—psoriasis	2.51e-05	0.000285	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—IL6—psoriasis	2.5e-05	0.000284	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TYK2—psoriasis	2.5e-05	0.000283	CbGpPWpGaD
Sirolimus—Pruritus—Prednisone—psoriasis	2.49e-05	8.42e-05	CcSEcCtD
Sirolimus—MTOR—Innate Immune System—CD4—psoriasis	2.48e-05	0.000281	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SOCS1—psoriasis	2.47e-05	0.000279	CbGpPWpGaD
Sirolimus—Feeling abnormal—Methotrexate—psoriasis	2.43e-05	8.19e-05	CcSEcCtD
Sirolimus—FGF2—Disease—NOS2—psoriasis	2.42e-05	0.000274	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HLA-B—psoriasis	2.42e-05	0.000274	CbGpPWpGaD
Sirolimus—Diarrhoea—Prednisone—psoriasis	2.41e-05	8.14e-05	CcSEcCtD
Sirolimus—Gastrointestinal pain—Methotrexate—psoriasis	2.41e-05	8.13e-05	CcSEcCtD
Sirolimus—Nausea—Betamethasone—psoriasis	2.4e-05	8.12e-05	CcSEcCtD
Sirolimus—Nausea—Dexamethasone—psoriasis	2.4e-05	8.12e-05	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—APOE—psoriasis	2.4e-05	0.000272	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—LEP—psoriasis	2.4e-05	0.000272	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD4—psoriasis	2.38e-05	0.000269	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CD4—psoriasis	2.37e-05	0.000268	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—IL6—psoriasis	2.35e-05	0.000266	CbGpPWpGaD
Sirolimus—Dizziness—Prednisone—psoriasis	2.33e-05	7.87e-05	CcSEcCtD
Sirolimus—Body temperature increased—Methotrexate—psoriasis	2.33e-05	7.86e-05	CcSEcCtD
Sirolimus—Abdominal pain—Methotrexate—psoriasis	2.33e-05	7.86e-05	CcSEcCtD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.31e-05	0.000262	CbGpPWpGaD
Sirolimus—Vomiting—Prednisone—psoriasis	2.24e-05	7.56e-05	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—NFKBIA—psoriasis	2.24e-05	0.000254	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HLA-A—psoriasis	2.24e-05	0.000254	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.22e-05	0.000252	CbGpPWpGaD
Sirolimus—Rash—Prednisone—psoriasis	2.22e-05	7.5e-05	CcSEcCtD
Sirolimus—Dermatitis—Prednisone—psoriasis	2.22e-05	7.49e-05	CcSEcCtD
Sirolimus—MTOR—Innate Immune System—JUN—psoriasis	2.22e-05	0.000251	CbGpPWpGaD
Sirolimus—Headache—Prednisone—psoriasis	2.21e-05	7.45e-05	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—CXCL8—psoriasis	2.18e-05	0.000247	CbGpPWpGaD
Sirolimus—Hypersensitivity—Methotrexate—psoriasis	2.17e-05	7.33e-05	CcSEcCtD
Sirolimus—CYP3A4—Metabolism—NDUFA5—psoriasis	2.16e-05	0.000245	CbGpPWpGaD
Sirolimus—FGF2—Immune System—TYK2—psoriasis	2.15e-05	0.000243	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CRP—psoriasis	2.14e-05	0.000242	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—NFKB1—psoriasis	2.13e-05	0.000242	CbGpPWpGaD
Sirolimus—Asthenia—Methotrexate—psoriasis	2.11e-05	7.13e-05	CcSEcCtD
Sirolimus—Nausea—Prednisone—psoriasis	2.09e-05	7.07e-05	CcSEcCtD
Sirolimus—Pruritus—Methotrexate—psoriasis	2.08e-05	7.03e-05	CcSEcCtD
Sirolimus—MTOR—Disease—HLA-A—psoriasis	2.07e-05	0.000234	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—NFKB1—psoriasis	2.05e-05	0.000232	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HLA-DRB1—psoriasis	2.04e-05	0.000232	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—IL6—psoriasis	2.04e-05	0.000232	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—JUN—psoriasis	2.02e-05	0.000229	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.02e-05	0.000229	CbGpPWpGaD
Sirolimus—Diarrhoea—Methotrexate—psoriasis	2.02e-05	6.8e-05	CcSEcCtD
Sirolimus—FGF2—Immune System—IFNG—psoriasis	2.01e-05	0.000228	CbGpPWpGaD
Sirolimus—FGF2—Disease—TYK2—psoriasis	1.98e-05	0.000225	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ICAM1—psoriasis	1.96e-05	0.000222	CbGpPWpGaD
Sirolimus—Dizziness—Methotrexate—psoriasis	1.95e-05	6.58e-05	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—NFKB1—psoriasis	1.95e-05	0.000221	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NFKBIA—psoriasis	1.95e-05	0.000221	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD4—psoriasis	1.94e-05	0.00022	CbGpPWpGaD
Sirolimus—MTOR—Disease—APOE—psoriasis	1.93e-05	0.000219	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CARM1—psoriasis	1.93e-05	0.000219	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL6—psoriasis	1.89e-05	0.000214	CbGpPWpGaD
Sirolimus—Vomiting—Methotrexate—psoriasis	1.87e-05	6.32e-05	CcSEcCtD
Sirolimus—Rash—Methotrexate—psoriasis	1.86e-05	6.27e-05	CcSEcCtD
Sirolimus—Dermatitis—Methotrexate—psoriasis	1.86e-05	6.26e-05	CcSEcCtD
Sirolimus—Headache—Methotrexate—psoriasis	1.85e-05	6.23e-05	CcSEcCtD
Sirolimus—CYP3A4—Metabolism—CYP2S1—psoriasis	1.84e-05	0.000208	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TYK2—psoriasis	1.83e-05	0.000208	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—STAT3—psoriasis	1.83e-05	0.000208	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SOCS1—psoriasis	1.83e-05	0.000207	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—LEP—psoriasis	1.82e-05	0.000206	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—APOE—psoriasis	1.82e-05	0.000206	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—IL6—psoriasis	1.8e-05	0.000204	CbGpPWpGaD
Sirolimus—MTOR—Disease—NOS2—psoriasis	1.8e-05	0.000204	CbGpPWpGaD
Sirolimus—FGF2—Disease—CD4—psoriasis	1.79e-05	0.000203	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CAT—psoriasis	1.79e-05	0.000203	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—VEGFA—psoriasis	1.77e-05	0.0002	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—STAT3—psoriasis	1.75e-05	0.000198	CbGpPWpGaD
Sirolimus—Nausea—Methotrexate—psoriasis	1.75e-05	5.91e-05	CcSEcCtD
Sirolimus—FGF2—Immune System—JUN—psoriasis	1.74e-05	0.000197	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.73e-05	0.000196	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NFKBIA—psoriasis	1.7e-05	0.000192	CbGpPWpGaD
Sirolimus—FGF2—Immune System—NFKB1—psoriasis	1.67e-05	0.00019	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CAT—psoriasis	1.64e-05	0.000186	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CXCL8—psoriasis	1.6e-05	0.000181	CbGpPWpGaD
Sirolimus—MTOR—Immune System—TYK2—psoriasis	1.59e-05	0.000181	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.53e-05	0.000173	CbGpPWpGaD
Sirolimus—FGF2—Immune System—STAT3—psoriasis	1.5e-05	0.00017	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IFNG—psoriasis	1.49e-05	0.000169	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—JUN—psoriasis	1.48e-05	0.000168	CbGpPWpGaD
Sirolimus—MTOR—Disease—TYK2—psoriasis	1.47e-05	0.000167	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CARM1—psoriasis	1.46e-05	0.000165	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD4—psoriasis	1.44e-05	0.000163	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NFKB1—psoriasis	1.43e-05	0.000162	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TYK2—psoriasis	1.39e-05	0.000157	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—APOE—psoriasis	1.39e-05	0.000157	CbGpPWpGaD
Sirolimus—FGF2—Disease—STAT3—psoriasis	1.39e-05	0.000157	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—LEP—psoriasis	1.35e-05	0.000153	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—APOE—psoriasis	1.35e-05	0.000153	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IL6—psoriasis	1.34e-05	0.000152	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—psoriasis	1.34e-05	0.000151	CbGpPWpGaD
Sirolimus—MTOR—Disease—CD4—psoriasis	1.33e-05	0.000151	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—psoriasis	1.3e-05	0.000147	CbGpPWpGaD
Sirolimus—MTOR—Immune System—JUN—psoriasis	1.29e-05	0.000146	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—STAT3—psoriasis	1.28e-05	0.000145	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IL6—psoriasis	1.28e-05	0.000145	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—APOE—psoriasis	1.28e-05	0.000144	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NFKBIA—psoriasis	1.26e-05	0.000143	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NFKB1—psoriasis	1.24e-05	0.000141	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL6—psoriasis	1.22e-05	0.000139	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PPARG—psoriasis	1.21e-05	0.000137	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CXCL8—psoriasis	1.21e-05	0.000137	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CAT—psoriasis	1.19e-05	0.000134	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—JUN—psoriasis	1.12e-05	0.000127	CbGpPWpGaD
Sirolimus—MTOR—Immune System—STAT3—psoriasis	1.12e-05	0.000127	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PPARG—psoriasis	1.11e-05	0.000126	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NFKB1—psoriasis	1.08e-05	0.000123	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL6—psoriasis	1.05e-05	0.000119	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TYK2—psoriasis	1.03e-05	0.000117	CbGpPWpGaD
Sirolimus—MTOR—Disease—STAT3—psoriasis	1.03e-05	0.000117	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—psoriasis	9.83e-06	0.000111	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—psoriasis	9.8e-06	0.000111	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—STAT3—psoriasis	9.73e-06	0.00011	CbGpPWpGaD
Sirolimus—FGF2—Disease—IL6—psoriasis	9.7e-06	0.00011	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—APOE—psoriasis	9.22e-06	0.000104	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCL8—psoriasis	8.98e-06	0.000102	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL6—psoriasis	8.97e-06	0.000102	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CARM1—psoriasis	8.97e-06	0.000102	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CAT—psoriasis	8.95e-06	0.000101	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—JUN—psoriasis	8.35e-06	9.46e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NFKB1—psoriasis	8.03e-06	9.1e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PPARG—psoriasis	8.03e-06	9.1e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6—psoriasis	7.8e-06	8.84e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—psoriasis	7.42e-06	8.41e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—psoriasis	7.29e-06	8.26e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—STAT3—psoriasis	7.22e-06	8.18e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6—psoriasis	7.2e-06	8.16e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—APOE—psoriasis	6.96e-06	7.88e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6—psoriasis	6.8e-06	7.7e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PPARG—psoriasis	6.06e-06	6.86e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CAT—psoriasis	5.52e-06	6.25e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—psoriasis	5.51e-06	6.24e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6—psoriasis	5.04e-06	5.71e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—APOE—psoriasis	4.29e-06	4.86e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPARG—psoriasis	3.73e-06	4.23e-05	CbGpPWpGaD
